Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers

Journal of Clinical Pharmacology

Volumn 46, Issue 4, 2006, Pages 456-460

  Klem, B ^a   Lappin, G ^b   Nicholson, S ^b   Van De Wetering, J ^c   De Vries, D E ^c   Oosterhuis, B ^c   Garner, R C ^b  

^a PhotoCure ASA   (Norway)

^b Xceleron Ltd   (United Kingdom)

^c PRA International USA   (Netherlands)

Author keywords

Accelerator mass spectrometry; Bioavailability; Bladder cancer; Fluorescence cystoscopy; HAL; Hexvix; Volunteer human study

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; CARBON 14; HEXAMINOLEVULINATE C 14; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 5-AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID; CARBON; DRUG DERIVATIVE; PHOTOSENSITIZING AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DETERMINATION; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; RADIATION DOSE; RADIOACTIVITY; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; ADOLESCENT; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; CROSSOVER PROCEDURE; HALF LIFE TIME; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED;

ADMINISTRATION, INTRAVESICAL; ADOLESCENT; ADULT; AMINOLEVULINIC ACID; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBON RADIOISOTOPES; CROSS-OVER STUDIES; HALF-LIFE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PHOTOSENSITIZING AGENTS;

EID: 33644973286     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006286849     Document Type: Article

References (18)

1. Al-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer. 2003;97(suppl 8):2064-2075.
2. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311-322.
3. Lerner S. Cystoscopy with PDD offers promise for improved bladder cancer detection. Business briefing: US kidney and urological disease 2005. Available at: www.touchbriefings.com.
4. Riley P, Potosky AL, Lubtz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995;33:828-841.
5. Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41:523-531.
6. Jichlinski P, Leisinger HJ. Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist! Urol Int. 2005;74:97-101.
7. Joudi FN, Konety BR. Fluorescence cystoscopy and bladder surveillance. Curr Opin Urol. 2004;14:265-270.
8. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study. J Urol. 2003;170:226-229.
9. Hexyl aminolevulinate: 5-ALA hexylester, 5-ALA hexylesther, aminolevulinic acid hexyl ester, hexaminolevulinate, hexyl 5-aminolevulinate, P 1206. Drugs R D. 2005;6:235-238.
10. Schmidbauer J, Witjes JA, Schmeller N, Donat R, Susani M, Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004;171:135-138.
11. Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005;174:862-866.
12. Lappin G, Garner RC. Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal Bioanal Chem. 2004;378:356-364.
13. Turteltaub KW, Vogel JS. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr Pharm Des. 2000;6:991-1007.
14. Lappin G, Garner RC. Ultra-sensitive detection of radiolabelled drugs and their metabolites using accelerator mass spectrometry. In: Wilson I, ed. Handbook of Analytical Separations. Amsterdam: Elsevier; 2003:331-349.
15. Vogel JS. Rapid production of graphite without contamination for biomedical AMS. Radiocarbon. 1992;34:344-350.
16. Marti A, Jichlinski P, Lange N, et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol. 2003;170:428-432.
17. Lappin G, Rowland M, Garner RC. The use of isotopes in the determination of absolute bioavailability. Expert Opin Drug Metab Toxicol. In press.
18. Collaud S, Lange N, Gurny R, Aymon D, Jichlinski P. An open pharmacokinetics study of 5-aminolevulinic acid hexyl ester induced- photodiagnosis after intravesical administration in patients with suspected bladder cancer. In press.